Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of CBT-1® in Combination With Doxorubicin in Patients With Locally Advanced or Metastatic, Unresectable Sarcomas Previously to Have Progressed on 150 mg/m2 or Less of Doxorubicin

NCT03002805 is registered in ClinicalTrials.gov with CBA Research as lead sponsor.

NCT NCT03002805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03002805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of CBT-1® in Combination With Doxorubicin in Patients With Locally Advanced or Metastatic, Unresectable Sarcomas Previously to Have Progressed on 150 mg/m2 or Less of Doxorubicin
Lead sponsor
CBA Research
Phase
Phase 1
Overall status
Unknown status
Start date
March 29, 2018
Completion date
September 30, 2020
Enrollment
46 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma